Literature DB >> 10348784

Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration.

R Wise1, J M Andrews, G Marshall, G Hartman.   

Abstract

A single 400-mg oral or intravenous (i.v.) dose of moxifloxacin was given to each of eight healthy male volunteers, and 6 weeks later the dose was administered by the other route. The concentrations of the drug in plasma, cantharidin-induced inflammatory fluid, and urine were measured over the subsequent 24 h. The mean maximum concentrations observed in plasma were 4.98 microg/ml after oral dosing and 5.09 microg/ml after i.v. dosing. The mean maximum concentrations attained in the inflammatory fluid were 2.62 and 3.23 microg/ml, respectively. The mean elimination half-lives from plasma were 8.32 and 8.17 h, respectively. The overall penetration into the inflammatory fluid was 103.4 and 104.2%. Over 24 h 15% of the drug was recovered in the urine when administered by either route.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348784      PMCID: PMC89310          DOI: 10.1128/AAC.43.6.1508

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).

Authors:  R Wise; D Mortiboy; J Child; J M Andrews
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po.

Authors:  C Catchpole; J M Andrews; J Woodcock; R Wise
Journal:  J Antimicrob Chemother       Date:  1994-01       Impact factor: 5.790

3.  In vitro activity of BAY 12-8039, a new fluoroquinolone.

Authors:  J M Woodcock; J M Andrews; F J Boswell; N P Brenwald; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

4.  In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

Authors:  A Dalhoff; U Petersen; R Endermann
Journal:  Chemotherapy       Date:  1996 Nov-Dec       Impact factor: 2.544

5.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

6.  Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.

Authors:  H Stass; A Dalhoff; D Kubitza; U Schühly
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

  6 in total
  35 in total

Review 1.  Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.

Authors:  A Aminimanizani; P Beringer; R Jelliffe
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

3.  Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.

Authors:  A Lubasch; I Keller; K Borner; P Koeppe; H Lode
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

4.  A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.

Authors:  Jeffrey S Litwin; Michael S Benedict; Michael D Thorn; Laura E Lawrence; Sue K Cammarata; Eugene Sun
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

5.  Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

Authors:  N Veziris; N Lounis; A Chauffour; C Truffot-Pernot; V Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae.

Authors:  Christina Kratzer; Wolfgang Graninger; Karin Macfelda; Astrid Buxbaum; Apostolos Georgopoulos
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

7.  In vivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model.

Authors:  Olivier Grossi; Jocelyne Caillon; Cedric Arvieux; Cedric Jacqueline; Denis Bugnon; Gilles Potel; Antoine Hamel
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

8.  Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.

Authors:  V Rodriguez-Cerrato; C C McCoig; I C Michelow; F Ghaffar; H S Jafri; R D Hardy; C Patel; K Olsen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model.

Authors:  Julien Brillault; Whocely Victor De Castro; Thomas Harnois; Alain Kitzis; Jean-Christophe Olivier; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

10.  Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.

Authors:  R Vick-Fragoso; G Hernández-Oliva; J Cruz-Alcázar; C F Amábile-Cuevas; P Arvis; P Reimnitz; J R Bogner
Journal:  Infection       Date:  2009-09-18       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.